EcoDrugPlus

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSDCDG00000030047
Gene Symbol: FNTA
3 Cross references
222 Possible Orthologues:

Fibroblast Growth Factor Receptor 1-A-Like

Ensembl ID : ENSDCDG00000031519
Gene Symbol: LOC114785337
3 Cross references
147 Possible Orthologues:

Fibroblast Growth Factor Receptor 1-A-Like

Ensembl ID : ENSDCDG00000020789
Gene Symbol: LOC114799026
3 Cross references
208 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSDCDG00000032762
Gene Symbol: FGFR2
1 Cross references
219 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSDCDG00000000206
Gene Symbol: FGFR2
1 Cross references
219 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSDCDG00000016838
Gene Symbol: FGFR3
3 Cross references
194 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSDCDG00000025035
Gene Symbol: FLT1
3 Cross references
199 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSDCDG00000033728
Gene Symbol: FLT4
3 Cross references
197 Possible Orthologues:

Folate Hydrolase 1b

Ensembl ID : ENSDCDG00000021176
Gene Symbol: FOLH1B
3 Cross references
340 Possible Orthologues:

Folate Receptor Alpha-Like

Ensembl ID : ENSDCDG00000028422
Gene Symbol: LOC114769596
3 Cross references
436 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSDCDG00000024134
Gene Symbol: LOC114770619
3 Cross references
319 Possible Orthologues:

Free Fatty Acid Receptor 3-Like

Ensembl ID : ENSDCDG00000029313
Gene Symbol: LOC114788858
2 Cross references
340 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).